Critical Points on the Use of Biologicals in Allergic Diseases and Asthma
10.4168/aair.2020.12.1.24
- Author:
Ioana AGACHE
1
;
Catalina COJANU
;
Alexandru LACULICEANU
;
Liliana ROGOZEA
Author Information
1. Department of Allergy and Clinical Immunology, Faculty of Medicine, Transylvania University of Brasov, Brasov, Romania. ibrumaru@unitbv.ro
- Publication Type:Review
- Keywords:
Biological products;
phenotype, precision medicine;
hypersensitivity;
asthma
- MeSH:
Adaptive Immunity;
Asthma;
Biological Products;
Hypersensitivity
- From:Allergy, Asthma & Immunology Research
2020;12(1):24-41
- CountryRepublic of Korea
- Language:English
-
Abstract:
Improved understanding of the contribution of immune-inflammatory mechanisms in allergic diseases and asthma has encouraged development of biologicals and small molecules specifically targeting the innate and adaptive immune response. There are several critical points impacting the efficacy of this stratified approach, from the complexity of disease endotypes to the effectiveness in real-world settings. We discuss here how these barriers can be overcome to facilitate the development of implementation science for allergic diseases and asthma.
